International medical humanitarian organization Médecins Sans Frontières (MSF) has criticized Japanese drugmaker Otsuka Pharmaceutical (TYO: 4768) for the 'ridiculously high price' of its tuberculosis drug Deltyba (delamanid).
It follows an announcement, earlier today, that Otsuka had signed a deal with the Stop TB Partnership to increase access to the experimental drug in low- and middle-income countries.
Delamanid, for the treatment of multi-drug-resistant tuberculosis (MDR-TB), has been priced at $1,700 per treatment course in developing countries.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze